To print: Select File and then Print from your browser's menu

Title: CHMP Issues Positive Opinion for Tysabri (Natalizumab) as a Treatment for Relapsing-Remitting Multiple Sclerosis

"CHMP Issues Positive Opinion for Tysabri (Natalizumab) as a Treatment for Relapsing-Remitting Multiple Sclerosis"

CAMBRIDGE, M.A., and DUBLIN, IRELAND -- April 28, 2006 -- Biogen Idec and Elan Corporation, plc announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), issued a positive opinion recommending marketing authorization for Tysabri® (natalizumab) as a treatment for relapsing-remitting multiple sclerosis (MS) to delay the progression of disability and reduce the frequency of relapses. The Committee recommended that Tysabri be used as single disease modifying therapy either in patients with highly active relapsing-remitting MS who have failed to respond to treatment with a beta-interferon, or in patients who have rapidly evolving severe relapsing-remitting MS. In making its recommendation, the CHMP reviewed available data from the development of Tysabri, including data from the Phase III AFFIRM monotherapy trial, the Phase III SENTINEL trial in which Tysabri was added to Avonex® (interferon beta-1a); and a comprehensive safety analysis, which included the assessments for cases of progressive multifocal leukoencephalopathy (PML). The CHMP also reviewed a Risk Management plan to assess and minimize risks, including PML and other serious opportunistic infections. The CHMP's positive recommendation for Tysabri will be considered for final marketing approval by the European Commission. Final approval customarily follows the CHMP's recommendation, which the companies anticipate will be this summer. The European Commission is the final decision-making body for all centrally-reviewed medicinal products that are to be introduced in the EU market. SOURCE: Biogen Idec and Elan Corporation, plc

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.